Story
Cardiac Dimensions was founded in 2000 with a mission of helping the millions of CHF patients worldwide who are either not surgical candidates or not fully benefiting from use of prescription medical management alone.
Cardiac Dimensions, Inc. is a venture-backed company developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure (CHF). This percutaneous approach to annuloplasty is accomplished by implanting a device in the great cardiac vein / coronary sinus via a catheter-based delivery system. The implant is designed to reshape the mitral annulus that surrounds the valve and reduce the mitral regurgitation.
Cardiac Dimensions, Inc. began European clinical trials of its CARILLON™ Mitral Contour System™ in 2005. Traditionally, patients suffering with mitral regurgitation may not be surgical candidates and rely on medical management treatment. This therapy may improve the symptoms associated with this condition.
More than 21 million people worldwide suffer from CHF, with more than 5 million cases in the U.S., and the number is growing rapidly. The development of mitral valve regurgitation is common in these patients and contributes significantly to the morbidity and mortality of people with CHF.